DelveInsight’s report, “Chronic Pulmonary Hypertension Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of chronic pulmonary hypertension (CPH). The report covers historical and projected epidemiology and highlights market trends across key regions, including the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
To Know in detail about the Chronic Pulmonary Hypertension market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Pulmonary Hypertension Market Forecast
Some of the key facts of the Chronic Pulmonary Hypertension Market Report:
-
The Chronic Pulmonary Hypertension (CPH) market is projected to grow at a significant CAGR from 2020 to 2034. In 2023, the total market size across the seven major markets (7MM) was approximately USD 28,290 million, with growth expected to continue throughout the forecast period. This expansion is driven by rising awareness of CPH, enhanced diagnostic capabilities, and the introduction of novel targeted therapies.
-
Within the EU4 and the UK, Germany held the largest market share in 2023 at 26%, while Spain accounted for the smallest share at 15%. Japan ranked second in the treatment market, representing roughly 12% of the 7MM total. In Japan, most prevalent cases in 2023 were classified as Group II (about 5,724 thousand cases), whereas Group I had the fewest cases, around 54 thousand.
-
DelveInsight’s analysis indicates that females constitute the majority of CPH cases compared to males. In the U.S., there were approximately 6,806 thousand male cases and 11,104 thousand female cases in 2023. The U.S. accounted for the largest proportion of diagnosed CPH cases across the 7MM (42%), followed by Japan (16%), with the UK leading among European countries at around 11%.
-
The U.S. also had the highest market value in 2023, estimated at USD 15,700 million, with further growth expected by 2034. Despite a high prevalence of roughly 42,476 thousand cases across the 7MM in 2023, the market for CPH-specific treatments remains limited, though emerging therapies are poised to drive substantial growth.
-
Key Companies: Bayer, Attgeno AB, Cereno Scientific AB, Bial – Portela C S.A, Liquidia Technologies, Bellerophon Therapeutics, AbbVie/Tenax Therapeutics, Insmed, Altavant Sciences, and others.
-
Key Therapies: ADEMPAS (riociguat), CS1, and others.
-
The CPH market is expected to expand significantly due to rising disease prevalence and awareness. The introduction of multiple late-stage pipeline therapies is also anticipated to transform market dynamics during the forecast period.
Chronic Pulmonary Hypertension Overview
Chronic pulmonary hypertension (CPH) is a disorder marked by elevated blood pressure in the lungs, placing additional strain on the heart and causing symptoms such as shortness of breath and fatigue. The condition is categorized into five groups: Group 1 – pulmonary arterial hypertension (PAH); Group 2 – pulmonary hypertension resulting from left heart disease; Group 3 – pulmonary hypertension associated with lung diseases or hypoxia; Group 4 – chronic thromboembolic pulmonary hypertension (CTEPH); and Group 5 – pulmonary hypertension with unclear or multifactorial causes. Early diagnosis and effective management are essential to improve patient outcomes and quality of life.
Diagnosing CPH involves comprehensive clinical evaluation, imaging studies, and specialized testing. Diagnosis can be challenging because symptoms are often nonspecific and must be distinguished from other cardiovascular or respiratory conditions. Common diagnostic tools include echocardiography, which assesses heart function and estimates pulmonary artery pressure, followed by confirmatory testing such as right heart catheterization, which provides direct measurement of pulmonary pressures. Accurate diagnosis requires careful interpretation, especially when other cardiac or pulmonary issues coexist, necessitating thorough differential analysis.
Get a Free sample for the Chronic Pulmonary Hypertension Market Forecast, Size & Share Analysis Report
Chronic Pulmonary Hypertension Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Chronic Pulmonary Hypertension Epidemiology Segmentation:
The Chronic Pulmonary Hypertension market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Diagnosed Prevalence of Chronic Pulmonary Hypertension in Adults
-
Diagnosed Prevalence of Chronic Pulmonary Hypertension in Pediatrics
-
Diagnosed Prevalence of Chronic Pulmonary Hypertension by Types
-
Diagnosed Prevalence of Chronic Pulmonary Hypertension by Location
-
Diagnosed Prevalence of Chronic Pulmonary Hypertension by Severity
Download the report to understand which factors are driving Chronic Pulmonary Hypertension epidemiology trends @ Chronic Pulmonary Hypertension Epidemiology Forecast
Chronic Pulmonary Hypertension Drugs Uptake and Pipeline Development Activities
The drug uptake section examines the adoption rate of newly launched or soon-to-be-launched therapies in the Chronic Pulmonary Hypertension (CPH) market. This analysis includes drug-specific uptake, patient adoption by therapy type, and sales performance for each medication.
The therapeutics assessment section highlights the drugs experiencing the fastest adoption and explores the factors driving their high usage. It also provides comparisons of drugs based on market share.
Additionally, the report covers pipeline development activities in CPH, offering insights into therapeutic candidates at various stages and the key companies involved in developing targeted treatments. Recent developments such as collaborations, mergers and acquisitions, licensing agreements, patent details, and other relevant information for emerging therapies are also analyzed.
Chronic Pulmonary Hypertension Therapies: ADEMPAS (riociguat), CS1, and others
Chronic Pulmonary Hypertension Key Companies: Bayer, Attgeno AB, Cereno Scientific AB, Bial – Portela C S.A, Liquidia Technologies, Bellerophon Therapeutics, AbbVie/Tenax Therapeutics, Insmed, Altavant Sciences
Discover more about therapies set to grab major Chronic Pulmonary Hypertension market share @ Chronic Pulmonary Hypertension Treatment Landscape
Chronic Pulmonary Hypertension Market Outlook
Phosphodiesterase-5 (PDE-5) inhibitors, including Sildenafil and Tadalafil, are effective in promoting vasodilation and reducing the proliferation of vascular smooth muscle cells. Endothelin receptor antagonists, such as Ambrisentan, Bosentan, and Macitentan, help counteract vasoconstriction and the mitogenic effects on pulmonary vascular smooth muscle. Commonly used calcium channel blockers like Nifedipine, Diltiazem, and Amlodipine are also employed in the treatment of Pulmonary Arterial Hypertension (PAH). Prostacyclins, including Epoprostenol, Treprostinil, and Iloprost, are recommended to enhance functional capacity and improve survival rates in pulmonary hypertension patients.
Additionally, IP prostacyclin receptor agonists activate the IP receptor to stimulate the prostacyclin pathway, while endothelin receptor antagonists reduce elevated endothelin-1 levels that contribute to vasoconstriction and structural changes in pulmonary vessels in PAH.
PDE-5 inhibitors and Guanylate Cyclase (sGC) stimulators act on the nitric oxide (NO) pathway, a natural vasodilator. NO increases cyclic GMP levels in cells, and PDE-5 inhibitors prevent its breakdown, enhancing vasodilation. sGC stimulators further promote cyclic GMP production by activating the sGC enzyme in endothelial cells, providing an additional therapeutic mechanism for PAH management.
Cereno Scientific’s lead candidate, CS1, is a Phase II therapy in development for PAH. The US FDA has granted Orphan Drug Designation (ODD) for CS1, enabling the company to focus on developing this treatment for the rare disease, with potential benefits for both patients and shareholders.
Scope of the Chronic Pulmonary Hypertension Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Chronic Pulmonary Hypertension Companies: Bayer, Attgeno AB, Cereno Scientific AB, Bial – Portela C S.A, Liquidia Technologies, Bellerophon Therapeutics, AbbVie/Tenax Therapeutics, Insmed, Altavant Sciences, and others
-
Key Chronic Pulmonary Hypertension Therapies: ADEMPAS (riociguat), CS1, and others
-
Chronic Pulmonary Hypertension Therapeutic Assessment: Chronic Pulmonary Hypertension current marketed and Chronic Pulmonary Hypertension emerging therapies
-
Chronic Pulmonary Hypertension Market Dynamics: Chronic Pulmonary Hypertension market drivers and Chronic Pulmonary Hypertension market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Chronic Pulmonary Hypertension Unmet Needs, KOL’s views, Analyst’s views, Chronic Pulmonary Hypertension Market Access and Reimbursement
To know more about Chronic Pulmonary Hypertension companies working in the treatment market, visit @ Chronic Pulmonary Hypertension Clinical Trials and Therapeutic Assessment
Table of Contents
1. Chronic Pulmonary Hypertension Market Report Introduction
2. Executive Summary for Chronic Pulmonary Hypertension
3. SWOT analysis of Chronic Pulmonary Hypertension
4. Chronic Pulmonary Hypertension Patient Share (%) Overview at a Glance
5. Chronic Pulmonary Hypertension Market Overview at a Glance
6. Chronic Pulmonary Hypertension Disease Background and Overview
7. Chronic Pulmonary Hypertension Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Pulmonary Hypertension
9. Chronic Pulmonary Hypertension Current Treatment and Medical Practices
10. Chronic Pulmonary Hypertension Unmet Needs
11. Chronic Pulmonary Hypertension Emerging Therapies
12. Chronic Pulmonary Hypertension Market Outlook
13. Country-Wise Chronic Pulmonary Hypertension Market Analysis (2020–2034)
14. Chronic Pulmonary Hypertension Market Access and Reimbursement of Therapies
15. Chronic Pulmonary Hypertension Market Drivers
16. Chronic Pulmonary Hypertension Market Barriers
17. Chronic Pulmonary Hypertension Appendix
18. Chronic Pulmonary Hypertension Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Chronic Pulmonary Hypertension Pipeline
“Chronic Pulmonary Hypertension Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Pulmonary Hypertension market. A detailed picture of the Chronic Pulmonary Hypertension pipeline landscape is provided, which includes the disease overview and Chronic Pulmonary Hypertension treatment guidelines.
Chronic Pulmonary Hypertension Epidemiology
DelveInsight’s ‘Chronic Pulmonary Hypertension Epidemiology Forecast to 2034’ report delivers an in-depth understanding of the disease, historical and forecasted Chronic Pulmonary Hypertension epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/